Article
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) - 28 Nov 2013
Charpentier Charlotte, Bertine Mélanie, Visseaux Benoit, Leleu Juliette, Larrouy Lucile, Peytavin Gilles, Mourez Thomas, Collin Gilles, Brun-Vézinet Françoise, Plantier Jean-C, Descamps Diane
Abstract excerpt
In this study, we assessed phenotypic susceptibility to dolutegravir and raltegravir in a large variety of HIV-1 'non-B' subtypes (n = 72) issued from integrase inhibitor-naive clinical isolates. All samples were susceptible to both dolutegravir and raltegravir with median IC50 values of 1.22 nmol/l and 1.53 nmol/l, respectively; similar to that observed for the B subtype. Thus, despite the high prevalence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.